SH01-TNDX

SH01-TNDX is an investigational drug candidate currently in development by Nanjing Sanhome Pharmaceutical. It is featured in the company's research and development pipeline, which primarily focuses on therapeutic areas such as oncology, anti-infectives, and metabolic diseases. While specific details regarding its mechanism of action and target have not been publicly disclosed, the "TNDX" suffix in its code name may suggest a focus on metabolic disorders, specifically diabetes (known as 'Tang Niao Bing' in Chinese), or potentially a target related to the TndX protein, a large resolvase found in *Clostridium difficile*, aligning with the company's established expertise in anti-infective therapies. As of early 2024, the drug is in the early stages of development, appearing on the company's pipeline visualization chart.